Now ideas for wellness

About Meiji

At a Glance

At a Glance

Get to know Meiji at a glance – from our core business to our most important numbers.

Blood Plasma Products

an photo of a blood plasma product

Blood plasma products are vital in the treatment of hematologic diseases. Meiji Group company KM Biologics launched Japan's first whole molecule (intact) intravenous human immunoglobulin formulation in 1980, the world's first therapeutic agent for congenital protein C deficiency in 2001, and the world's first hemophilia inhibitor hemostatic agent in 2014. We also collaborate with other companies to support Japan's domestic self-sufficiency in albumin products.

Our Products

Human Coagulation Factor VIIa containing Factor X

Control of bleeding episodes in patients with blood coagulation factor VIII or factor IX deficiency with inhibitors

Human Coagulation Factor IX

Control of bleeding episodes in patients with blood coagulation factor IX deficiency

Human Coagulation Factor VIII/von Willebrand Factor Complex
  1. Control of bleeding episodes in patients with blood coagulation factor VIII deficiency
  2. Control of bleeding episodes in patients with von Willebrand disease
Human Activated Protein C

The following diseases caused by congenital protein C deficiency:

  1. Deep vein thrombosis, acute pulmonary thromboembolism
  2. Purpuric purpura
Fibrin Sealant (Human)

Tissue adhesion and closure

Intravenous Immunoglobulin (Human)
  1. Hypogammaglobulinemia or agammaglobulinemia
  2. Combined use with antibiotics in severe infections
  3. Idiopathic thrombocytopenic purpura (when other medications are ineffective and there is a remarkable bleeding tendency and temporary hemostasis management such as surgical treatment or delivery is required)
  4. Acute Kawasaki disease (in severe cases with a risk of coronary artery dysfunction)
  5. Guillain-Barre syndrome (in severe cases causing difficulties walking in the acute exacerbation phase)
  6. Improvement of neuropathy in eosinophilic polyangiitis granulomatosis (only when steroid drugs are ineffective)
  7. Chronic inflammatory demyelinating polyneuropathy (including multifocal motor neuropathy (MMN))
  8. Acute phase of optic neuritis (in cases where the effect of steroids is insufficient)
Intravenous Pepsin Treated Immuno Globulin (Human)
  1. Hypogammaglobulinemia or agammaglobulinemia
  2. Combined use with antibiotics in severe infections
Human Albumin
  1. Hypoalbuminemia due to loss of albumin (burn injuries, nephrotic syndrome, etc.) and reduced albumin synthesis (liver cirrhosis, etc.)
  2. Hemorrhagic shock
  • an photo two men of KM Biologics
  • Our Support for Hemophilia Patients

    Hemostasis treatment facilitates coagulation, the natural clotting of the blood to stem bleeding, a long-standing issue for hemophilia patients with inhibitors. In 2014, KM Biologics launched Byclot®, Japan's first hemophilia inhibitor product, which is made by extracting blood coagulation factors from donated plasma. As the factors are present in tiny quantities, the manufacturing process uses advanced technologies like immunoaffinity chromatography. Byclot® has made a hugely positive impact on the lives of hemophilia patients in Japan.